ANN ARBOR, Mich., Nov. 16, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous cell products for the treatment of severe, chronic cardiovascular diseases, announced today that Amit N. Patel, M.D., M.S., Associate Professor of Surgery at the University of Utah School of Medicine and the National Principal Investigator of the Company’s U.S. Phase II IMPACT-DCM clinical trial provided an oral presentation on Sunday evening at the American Heart Association (AHA) Scientific Sessions 2009. Dr. Patel presented encouraging interim data suggesting that the majority of patients treated to date with Cardiac Repair Cells (CRCs) have shown improvements in their heart failure classification, while patients in the control group, who did not receive CRCs, did not have a similarly improved outcome.
